Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

629 related articles for article (PubMed ID: 36275727)

  • 1. Target tumor microenvironment by innate T cells.
    Li YR; Wilson M; Yang L
    Front Immunol; 2022; 13():999549. PubMed ID: 36275727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity.
    Li YR; Brown J; Yu Y; Lee D; Zhou K; Dunn ZS; Hon R; Wilson M; Kramer A; Zhu Y; Fang Y; Yang L
    Cancers (Basel); 2022 Jun; 14(11):. PubMed ID: 35681730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering the Bridge between Innate and Adaptive Immunity for Cancer Immunotherapy: Focus on γδ T and NK Cells.
    Morandi F; Yazdanifar M; Cocco C; Bertaina A; Airoldi I
    Cells; 2020 Jul; 9(8):. PubMed ID: 32707982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment.
    Wang Y; Li YR
    Curr Pharm Biotechnol; 2024 Jan; ():. PubMed ID: 38310449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy.
    Li YR; Yu Y; Kramer A; Hon R; Wilson M; Brown J; Yang L
    Cells; 2022 May; 11(9):. PubMed ID: 35563889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Yu J; Zhu Y; Lee D; Zhu E; Li Z; Kim YJ; Zhou K; Fang Y; Lyu Z; Chen Y; Tian Y; Huang J; Cen X; Husman T; Cho JM; Hsiai T; Zhou JJ; Wang P; Puliafito BR; Larson SM; Yang L
    Mol Ther; 2024 Jun; 32(6):1849-1874. PubMed ID: 38584391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-Host Disease Modulation by Innate T Cells.
    Fang Y; Zhu Y; Kramer A; Chen Y; Li YR; Yang L
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy.
    Pan K; Farrukh H; Chittepu VCSR; Xu H; Pan CX; Zhu Z
    J Exp Clin Cancer Res; 2022 Mar; 41(1):119. PubMed ID: 35361234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal-associated invariant T cells for cancer immunotherapy.
    Li YR; Zhou K; Wilson M; Kramer A; Zhu Y; Dawson N; Yang L
    Mol Ther; 2023 Mar; 31(3):631-646. PubMed ID: 36463401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repolarization of Tumor-Infiltrating Myeloid Cells for Augmentation of CAR T Cell Therapies.
    Luo W; Napoleon JV; Zhang F; Lee YG; Wang B; Putt KS; Low PS
    Front Immunol; 2022; 13():816761. PubMed ID: 35250995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.
    Delfanti G; Dellabona P; Casorati G; Fedeli M
    Front Med (Lausanne); 2022; 9():897750. PubMed ID: 35615083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
    Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
    Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orthotopic and Heterotopic Murine Models of Pancreatic Cancer Exhibit Different Immunological Microenvironments and Different Responses to Immunotherapy.
    Wang J; Liu X; Ji J; Luo J; Zhao Y; Zhou X; Zheng J; Guo M; Liu Y
    Front Immunol; 2022; 13():863346. PubMed ID: 35874730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment.
    Antoñana-Vildosola A; Zanetti SR; Palazon A
    Int Rev Cell Mol Biol; 2022; 370():123-147. PubMed ID: 35798503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.